Edobacomab: Difference between revisions

Revision as of 17:47, 13 September 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID\|Chem/Drugbox validation← Previous edit		Revision as of 20:55, 16 October 2011 edit undoThe chemistds (talk \| contribs)Extended confirmed users5,761 edits No ChemSpider ID for this recordNext edit →
Line 28:		Line 28:

	<!--Identifiers-->		<!--Identifiers-->
			\| ChemSpiderID = NA
	\| CAS_number = 141410-98-2		\| CAS_number = 141410-98-2
	\| ATC_prefix = none		\| ATC_prefix = none

Revision as of 20:55, 16 October 2011

Pharmaceutical compound

Edobacomab, codenamed E5, is a mouse monoclonal antibody that was investigated as a possible treatment for sepsis caused by Gram-negative bacterial infections.

Greenman RL; Schein RM; Martin MA; et al. (1991). "A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group". JAMA. 266 (8): 1097–102. doi:10.1001/jama.266.8.1097. PMID 1865542. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
Bone RC; Balk RA; Fein AM; et al. (1995). "A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group". Crit. Care Med. 23 (6): 994–1006. PMID 7774238. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
Angus DC; Birmingham MC; Balk RA; et al. (2000). "E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators". JAMA. 283 (13): 1723–30. doi:10.1001/jama.283.13.1723. PMID 10755499. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.